How to Get Tesamorelin in the US

Most pages on this site about “how to get” a peptide end up in the same place: the compound isn’t FDA-approved, so the only arguably legitimate route runs through a licensed prescriber and a compounding pharmacy, and the catch is whether that pharmacy is currently allowed to make it. Tesamorelin breaks that pattern. It’s a real, FDA-approved prescription drug. That single fact reshuffles every route below, so it’s worth understanding before you weigh your options.

Why tesamorelin is the exception

Tesamorelin is the only FDA-approved peptide in the growth-hormone-releasing-hormone (GHRH) family. It’s sold under the brand name Egrifta, and the current formulation on the US market is Egrifta WR, which the FDA approved in 2025 to replace the earlier Egrifta SV. The drug is a stabilized analog of GHRH that prompts the pituitary to release the body’s own growth hormone in a roughly natural rhythm.

The approval is narrow. Tesamorelin is approved for one indication: reducing excess abdominal fat (visceral adipose tissue) in adults with HIV who have lipodystrophy — the fat-redistribution syndrome that can accompany long-term HIV treatment. That’s the entire approved use. Everything you may have read about tesamorelin for general weight loss, “anti-aging,” body recomposition, or growth-hormone optimization in healthy adults sits outside the approved label.

That distinction is the hinge for the rest of this page. For an approved drug, the clean route is simply a prescription filled at a pharmacy. For any use beyond the approved indication, you’re in off-label territory — still legal for a doctor to prescribe, but no longer something the approval, the labeling, or your insurer is built around.

Note: “FDA-approved” and “approved for what you want it for” are two different things. Tesamorelin clears the first bar comfortably and the second only for HIV-associated lipodystrophy.

Route 1 — The approved-indication prescription (the clean path)

If you have HIV-associated lipodystrophy, tesamorelin behaves like any other branded prescription drug. Your HIV specialist or another treating physician evaluates you, decides whether it’s appropriate, and writes a prescription for Egrifta. A regular pharmacy — often a specialty pharmacy, given the cost and handling — dispenses the manufacturer’s product. There’s no compounding question, no Category 2 list to worry about, no gray-market vial of uncertain origin. You’re getting the same FDA-approved drug that was studied in the trials that won approval.

This is the only route where the full weight of regulation is on your side: an approved product, an approved indication, official labeling, and a pharmacovigilance system behind it. It’s also the route where insurance is most likely (though far from guaranteed) to help, usually after a prior-authorization process that confirms the diagnosis.

If this describes you, the “how to get it” question is mostly a coverage-and-pharmacy question, not a legality question. The harder problems are prior authorization and cost, not access.

Route 2 — Off-label prescribing (legal, but a different deal)

This is where most people asking “how do I get tesamorelin” actually land: they don’t have HIV-associated lipodystrophy, but they’re interested in tesamorelin for visceral belly fat, metabolic reasons, or GH-axis support.

Off-label prescribing is a normal, lawful part of US medicine. A licensed clinician may prescribe an approved drug for an unapproved indication when, in their professional judgment, it’s appropriate for the patient. So a physician can legally prescribe Egrifta off-label. Telehealth wellness and longevity clinics are the usual setting for this, and a legitimate one will still want a real evaluation — history, goals, often baseline labs including IGF-1, and ongoing monitoring — before and during treatment.

But off-label tesamorelin is a meaningfully different proposition than the approved-indication route:

• You’re paying cash. Insurers cover drugs for approved indications; off-label cosmetic or metabolic use of a high-cost brand drug is almost never covered.
• The price is steep. Brand Egrifta has no generic. As of 2026, cash pricing commonly runs in the low-thousands-of-dollars-per-month range, which is why this route prices many people out and pushes them toward cheaper, riskier channels (Route 3). Our tesamorelin cost page breaks the numbers down.
• The evidence base is narrower than the marketing. The strong efficacy and safety data are in the HIV-lipodystrophy population it was studied in. Extrapolating that to healthy adults seeking fat loss is an assumption, not a proven result. The honest framing is on what tesamorelin is and tesamorelin for belly fat.

If you go this route, the quality of the provider matters more than anything. The mechanics of finding and vetting one are general enough that we cover them separately in how to get any peptide prescribed and how to choose a peptide clinic; a clinic that prescribes off-label without any evaluation is the warning sign, not the convenience.

Route 3 — “Research” and gray-market vials (the cheap, unregulated channel)

Search for tesamorelin and you’ll quickly hit sites selling vials at a fraction of Egrifta’s price, usually labeled “for research use only, not for human consumption.” This is a genuinely different channel from the two above, and the approved-drug status actually makes it more legally awkward, not less.

Here’s the nuance. For unapproved peptides, the legitimate debate is about whether a 503A or 503B pharmacy may compound them under the bulk-substances rules. Tesamorelin is the active ingredient of an FDA-approved drug, which changes the compounding analysis entirely — the simple “no approved alternative” rationale that some compounding leans on doesn’t fit when an approved product already exists. So the cheap vials circulating online generally aren’t pharmacy-compounded prescriptions filled for you after an evaluation; they’re research-chemical-market product.

The problems with that channel are the same ones we flag across this site, and they’re not hypothetical:

• Unknown concentration and purity. A vial labeled “tesamorelin” from an unregulated supplier may contain less, more, or something other than what the label claims. There’s no enforced manufacturing standard behind it.
• No clinical oversight. Buying and self-injecting without evaluation means no one is monitoring IGF-1, side effects, or contraindications.
• No recourse. If a product is contaminated or mislabeled, there’s no recall system and no accountable party.

We don’t provide sourcing guidance for this channel, and we’d steer anyone away from it. The point of laying it out is so you can recognize it for what it is when a price looks too good to be true: it’s the unregulated lane, not a discount on the real drug.

How the routes compare

The throughline: the two legitimate routes both deliver the same approved drug; they differ in indication and who pays, not in product quality. The third route differs in the product itself.

What to confirm before you commit

• Which indication applies to you. If it’s HIV-associated lipodystrophy, you’re on the clean path and the conversation is about coverage. If not, you’re choosing off-label — go in clear-eyed about cost and the thinner evidence.
• That a real evaluation is happening. Any prescriber, off-label or not, should assess you and monitor you. Tesamorelin raises IGF-1, and there are populations (such as people with active malignancy) where it’s contraindicated. “Just buy and inject” is the thing to avoid.
• What you’re actually buying. A pharmacy dispensing Egrifta against a prescription is one thing. A website shipping a “research” vial is another. The price gap usually tells you which you’re looking at.
• Current status. Drug approvals, formulations (Egrifta SV vs WR), and pricing shift over time. This page is current as of its last-updated date and may change; verify specifics with a licensed provider or pharmacy.

For the prescriber-side mechanics that apply regardless of which peptide you’re after, see how to get any peptide prescribed, and for the bigger legal picture, are peptides legal in the US?.